Last Updated on September 6, 2022 by GlobeNewsWire
WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:
H.C. Wainwright 24th Annual Global Investment ConferenceForum: Corporate PresentationDate: Monday, September 12, 2022Time: 7:00 a.m. ETBaird 2022 Global Healthcare ConferenceForum: Corporate PresentationDate: Wednesday, September 14, 2022Time: 1:25 p.m. ETGuggenheim Nantucket Therapeutics ConferenceForum: Fireside ChatDate: Thursday, September 29, 2022Time: 10:30 a.m. ETBenzinga Retail Conference (Virtual)Forum: Fireside ChatDate: Friday, September 30, 2022Time: 11:40 a.m. ET
A webcast and subsequent archived replay of the corporate presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert(R) technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients’ eyes across four U.S. FDA approved products, including YUTIQ(R) for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Christina TartagliaStern IRDirect: firstname.lastname@example.org
Amy PhillipsGreen Room CommunicationsDirect: email@example.com